The Europe Cancer Gene Therapy Market would witness market growth of 20.3% CAGR during the forecast period (2022-2028).
Favorable government therapeutic laws would further enhance numerous prospects, resulting in the expansion of the cancer gene therapy market over the projection period. However, high treatment costs and undesired immune reactions are projected to limit the growth of the cancer gene therapy market. In addition, compared to prior years, there was an increase in novel gene therapy pipeline developments in 2020. As a result, the number of clinical trials, product launches, collaborations, and product innovations are increasing.
Over the last few years, the gene therapy market has seen a series of changes. Initially, gene therapy for monogenetic illnesses was popular; however, the market for gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by putting therapeutic DNA into their bodies.
The German cancer gene has a lot of room for growth in the coming years. One of the primary reasons driving country growth is a better regulatory environment. Over the last few years, German regulatory authorities have simplified the regulatory process, making it easier for industry participants to advertise their medicines in Germany. Furthermore, a growing interest among healthcare experts in the availability of advanced cancer gene therapy would help the country prosper.
Lung cancer is caused by the uncontrollable proliferation of aberrant cells in one or both lungs. Persons who smoke have the highest risk of lung cancer, despite the fact that it can affect people who have never smoked. The time and number of cigarettes smoked by a patient increase the risk of lung cancer. Other risk factors include secondhand smoke, asbestos, certain metals, some organic compounds, radiation, air pollution, and diesel exhaust at the workplace or in the environment.
The Germany market dominated the Europe Cancer Gene Therapy Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $324.3 million by 2028. The UK market is poised to grow at a CAGR of 19.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 21.2% during (2022 - 2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Cancer Gene Therapy Market Size will Hit $5 Billion by 2028, at a CAGR of 21.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy, and
- Gene Transfer
By End User
- Hospitals
- Diagnostic centers
- Research Institutes
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Cancer Gene Therapy Market, by Therapy
1.4.2 Europe Cancer Gene Therapy Market, by End User
1.4.3 Europe Cancer Gene Therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Cancer Gene Therapy Market by Therapy
3.1 Europe Gene Induced Immunotherapy Market by Country
3.2 Europe Oncolytic Virotherapy Market by Country
3.3 Europe Gene Transfer Market by Country
Chapter 4. Europe Cancer Gene Therapy Market by End User
4.1 Europe Hospitals Market by Country
4.2 Europe Diagnostic centers Market by Country
4.3 Europe Research Institutes Market by Country
Chapter 5. Europe Cancer Gene Therapy Market by Country
5.1 Germany Cancer Gene Therapy Market
5.1.1 Germany Cancer Gene Therapy Market by Therapy
5.1.2 Germany Cancer Gene Therapy Market by End User
5.2 UK Cancer Gene Therapy Market
5.2.1 UK Cancer Gene Therapy Market by Therapy
5.2.2 UK Cancer Gene Therapy Market by End User
5.3 France Cancer Gene Therapy Market
5.3.1 France Cancer Gene Therapy Market by Therapy
5.3.2 France Cancer Gene Therapy Market by End User
5.4 Russia Cancer Gene Therapy Market
5.4.1 Russia Cancer Gene Therapy Market by Therapy
5.4.2 Russia Cancer Gene Therapy Market by End User
5.5 Spain Cancer Gene Therapy Market
5.5.1 Spain Cancer Gene Therapy Market by Therapy
5.5.2 Spain Cancer Gene Therapy Market by End User
5.6 Italy Cancer Gene Therapy Market
5.6.1 Italy Cancer Gene Therapy Market by Therapy
5.6.2 Italy Cancer Gene Therapy Market by End User
5.7 Rest of Europe Cancer Gene Therapy Market
5.7.1 Rest of Europe Cancer Gene Therapy Market by Therapy
5.7.2 Rest of Europe Cancer Gene Therapy Market by End User
Chapter 6. Company Profiles
6.1 Novartis AG
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 GlaxoSmithKline PLC (GSK)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Amgen, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Bristol Myers Squibb Company
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.5 Karyopharm Therapeutics, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expense
6.6 Gilead Sciences, Inc.
6.6.1 Company overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Adaptimmune Limited
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Genelux Corporation
6.8.1 Company Overview
6.9 Sarepta Therapeutics, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Research & Development Expenses
TABLE 1 Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 2 Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 3 Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 4 Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 5 Europe Gene Induced Immunotherapy Market by Country, 2018 - 2021, USD Million
TABLE 6 Europe Gene Induced Immunotherapy Market by Country, 2022 - 2028, USD Million
TABLE 7 Europe Oncolytic Virotherapy Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Oncolytic Virotherapy Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Gene Transfer Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Gene Transfer Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 12 Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 13 Europe Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Diagnostic centers Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Diagnostic centers Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Research Institutes Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Research Institutes Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Cancer Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Cancer Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 Germany Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 22 Germany Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 23 Germany Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 24 Germany Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 25 Germany Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 26 Germany Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 27 UK Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 28 UK Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 29 UK Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 30 UK Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 31 UK Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 32 UK Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 33 France Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 34 France Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 35 France Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 36 France Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 37 France Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 38 France Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 39 Russia Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 40 Russia Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 41 Russia Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 42 Russia Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 43 Russia Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 44 Russia Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 45 Spain Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 46 Spain Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 47 Spain Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 48 Spain Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 49 Spain Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 50 Spain Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 51 Italy Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 52 Italy Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 53 Italy Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 54 Italy Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 55 Italy Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 56 Italy Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 57 Rest of Europe Cancer Gene Therapy Market, 2018 - 2021, USD Million
TABLE 58 Rest of Europe Cancer Gene Therapy Market, 2022 - 2028, USD Million
TABLE 59 Rest of Europe Cancer Gene Therapy Market by Therapy, 2018 - 2021, USD Million
TABLE 60 Rest of Europe Cancer Gene Therapy Market by Therapy, 2022 - 2028, USD Million
TABLE 61 Rest of Europe Cancer Gene Therapy Market by End User, 2018 - 2021, USD Million
TABLE 62 Rest of Europe Cancer Gene Therapy Market by End User, 2022 - 2028, USD Million
TABLE 63 Key Information – Novartis AG
TABLE 64 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 65 Key Information – Amgen, Inc.
TABLE 66 Key Information – Bristol Myers Squibb Company
TABLE 67 key Information – Karyopharm Therapeutics, Inc.
TABLE 68 Key Information – Gilead Sciences, Inc.
TABLE 69 Key information – Adaptimmune Limited
TABLE 70 Key Information – Genelux Corporation
TABLE 71 key information – Sarepta Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Novartis AG
FIG 3 Recent strategies and developments: Bristol Myers Squibb Company